Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment

Trial Profile

Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Sep 2019 Planned primary completion date changed from 31 Aug 2019 to 31 Dec 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 20 Aug 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top